Adverum Biotechnologies Grants License to Ray Therapeutics Inc. for the AAV.7m8 Intravitreal Capsid
12 Junio 2023 - 7:00AM
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage
company that aims to establish gene therapy as a new standard of
care for highly prevalent ocular diseases, announces an agreement
granting Ray Therapeutics a non-exclusive, royalty bearing license
of Adverum’s proprietary AAV.7m8 intravitreal (IVT) vector capsid
to be used in conjunction with Ray’s optogenetics payload.
“This deal highlights the value of Adverum’s AAV.7m8 gene
therapy platform, a capsid for IVT delivery, in a variety of ocular
gene therapy indications,” commented Laurent Fischer, M.D.,
president and chief executive officer of Adverum Biotechnologies.
“A single IVT injection of Ixo-vec in the Phase 1 OPTIC study for
wet age-related macular degeneration has been well tolerated and
has led to stable and persistent aflibercept protein levels through
at least three years. Ixo-vec is currently being evaluated in the
ongoing Phase 2 LUNA trial. This marks the sixth asset delivered
via AAV.7m8, including our Ixo-vec candidate for the treatment of
wet age-related macular degeneration, Gensight’s GS030, an
optogenetic asset for retinitis pigmentosa, both of which have
shown promising results in early clinical trials, as well as
Adverum’s own investigational pre-clinical pipeline assets in dry
AMD, optogenetics and blue cone monochromacy.”
“Visual optogenetics is a disruptive technology which affords
the opportunity to restore life-transforming levels of vision to
blind and visually impaired patients with conditions such as
retinitis pigmentosa,” said Paul Bresge, chief executive officer of
Ray Therapeutics. “We have developed a next generation
bioengineered optogenetic payload which we believe is optimized for
human vision. When delivered using previously studied low doses of
AAV.7m8, we anticipate levels of target retinal ganglion cell
transduction that could realize the full potential of our RTx-015
asset.”
Under the terms of the agreement, Adverum grants Ray
Therapeutics a worldwide, non-exclusive license of AAV.7m8 for the
prevention, treatment, diagnosis or amelioration of any ocular
disorder utilizing Ray’s optogenetics approach.
About Adverum BiotechnologiesAdverum
Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that
aims to establish gene therapy as a new standard of care for highly
prevalent ocular diseases with the aspiration of developing
functional cures to restore vision and prevent blindness.
Leveraging the capabilities of its proprietary, intravitreal (IVT)
platform, Adverum is developing durable, single-administration
therapies, designed to be delivered in physicians’ offices, to
eliminate the need for frequent ocular injections to treat these
diseases. Adverum is evaluating its novel gene therapy candidate,
ixoberogene soroparvovec (Ixo-vec, formerly referred to as
ADVM-022), as a one-time, IVT injection for patients with
neovascular or wet age-related macular degeneration. Additionally,
by overcoming the challenges associated with current treatment
paradigms for debilitating ocular diseases, Adverum aspires to
transform the standard of care, preserve vision, and create a
profound societal impact around the globe. For more information,
please visit www.adverum.com.
About Ray Therapeutics Ray Therapeutics is
developing novel optogenetics gene therapies for patients with
blinding diseases. The company is developing its lead candidate
RTx-015 in retinitis pigmentosa, a degenerative retinal disease
with significant unmet medical need. The company’s mission is to
use optogenetics to restore vision, independent of genetic mutation
for patients with inherited retinal diseases. Ray Therapeutics is
based in San Francisco, California. For additional information,
visit www.raytherapeutics.com.
Forward-looking Statements Statements contained
in this press release regarding events or results that may occur in
the future are “forward-looking statements” within the meaning of
the Private Securities Litigation Reform Act of 1995. Such
statements include but are not limited to statements regarding the
potential benefits of AAV.7m8 as a potent capsid. Actual results
could differ materially from those anticipated in such
forward-looking statements as a result of various risks and
uncertainties, including risks inherent to, without limitation:
Adverum’s novel technology, which makes it difficult to predict the
outcome of clinical trials; regulatory uncertainties; the results
of early clinical trials not always being predictive of future
clinical trials and results; and the potential for future
complications or side effects in connection with use of AAV.7m8.
Additional risks and uncertainties facing Adverum are set forth
under the caption “Risk Factors” and elsewhere in Adverum’s
Securities and Exchange Commission (SEC) filings and reports,
including Adverum’s Quarterly Report on Form 10-Q for the quarter
ended March 31, 2023 filed with the SEC on May 11, 2023. All
forward-looking statements contained in this press release speak
only as of the date on which they were made. Adverum undertakes no
obligation to update such statements to reflect events that occur
or circumstances that exist after the date on which they were
made.
Adverum Corporate, Investor and Media
InquiriesAnand ReddiVice President, Head of Corporate
Strategy, External Affairs and EngagementAdverum Biotechnologies,
Inc.T: 650-649-1358E: areddi@adverum.com
Ray Therapeutics Media InquiriesKimberly HaKKH
Advisors917-291-5744kimberly.ha@kkhadvisors.com
Adverum Biotechnologies (NASDAQ:ADVM)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Adverum Biotechnologies (NASDAQ:ADVM)
Gráfica de Acción Histórica
De May 2023 a May 2024